Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research

Progress in Lipid Research

Volumn 59, Issue , 2015, Pages 106-125

  Willebrords, Joost ^a   Pereira, Isabel Veloso Alves ^b   Maes, Michaël ^a   Crespo Yanguas, Sara ^a   Colle, Isabelle ^c   Van Den Bossche, Bert ^c   Da Silva, Tereza Cristina ^b   De Oliveira, Cláudia Pinto Marques Souza ^b   Andraus, Wellington ^b   Vinken, Mathieu ^a   Alves, Venâncio Avancini ^b   Cogliati, Bruno ^b  

^a FACULTY OF MEDICINE AND PHARMACY   (Belgium)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Algemeen Stedelijk Ziekenhuis   (Belgium)

Author keywords

Biomarkers; Drugs; Models; Non alcoholic fatty liver disease; Steatosis

Indexed keywords

ALPIDEM; AMINEPTINE; AMIODARONE; BIOLOGICAL MARKER; BUPRENORPHINE; CLOZAPINE; CYCLOHEXIMIDE; DISULFIRAM; FIALURIDINE; IRINOTECAN; LEPTIN; METHOTREXATE; MICRORNA 122; NILUTAMIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OROTIC ACID; PERHEXILINE; TACRINE; TAMOXIFEN; TETRACYCLINE DERIVATIVE; THIOACETAMIDE; TIANEPTINE; TRIACYLGLYCEROL; TROGLITAZONE; VALPROIC ACID; FATTY ACID;

ARTICLE; COCULTURE; DIET; DISEASE MODEL; DNA METHYLATION; FAST FOOD; FAT INTAKE; FATTY ACID OXIDATION; FRUCTOSE RICH DIET; GENETIC ASSOCIATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; LIPID DIET; LIPID PEROXIDATION; LIVER CELL CULTURE; LIVER FIBROSIS; LIVER SLICE; LIVER TOXICITY; METABOLOMICS; METHIONINE CHOLINE DEFICIENT DIET; METHYL DEFICIENT DIET; MONOLAYER CULTURE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; RODENT; TRANSCRIPTOMICS; TRANSGENIC ANIMAL; WESTERN DIET; ZEBRA FISH; ADVERSE EFFECTS; ANIMAL; BLOOD; LIPID METABOLISM; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ANIMALIA; DANIO RERIO; RODENTIA;

ANIMALS; BIOMARKERS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY ACIDS; HUMANS; LIPID METABOLISM; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; VALPROIC ACID;

EID: 84934283686     PISSN: 01637827     EISSN: 18732194     Source Type: Journal    
DOI: 10.1016/j.plipres.2015.05.002     Document Type: Review

References (324)

1. R. Loomba, and A.J. Sanyal The global NAFLD epidemic Nat. Rev. Gastroenterol. Hepatol. 10 2013 686 690
2. G. Vernon, A. Baranova, and Z.M. Younossi Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults Aliment. Pharmacol. Ther. 34 2011 274 285
3. S. Milić, and D. Stimac Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment Dig. Dis. 30 2012 158 162
4. G. Bedogni, and S. Bellentani Fatty liver: how frequent is it and why? Ann. Hepatol. 3 2004 63 65
5. S. Bellentani, G. Bedogni, L. Miglioli, and C. Tiribelli The epidemiology of fatty liver Eur. J. Gastroenterol. Hepatol. 16 2004 1087 1093
6. E. Björnsson The natural history of drug-induced liver injury Semin. Liver Dis. 29 2009 357 363
7. D. Schuppan, and J.M. Schattenberg Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches J. Gastroenterol. Hepatol. 28 Suppl 1 2013 68 76
8. M. Obika, and H. Noguchi Diagnosis and evaluation of nonalcoholic fatty liver disease Exp. Diabetes Res. 2012 2012 145754
9. E. Lebovics, and J. Rubin Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do Diabetes Metab. Res. Rev. 27 2011 419 424
10. L.A. Adams, and A.E. Feldstein Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis J. Dig. Dis. 12 2011 10 16
11. A. Tannapfel, H. Denk, H.P. Dienes, C. Langner, P. Schirmacher, and M. Trauner Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease Virchows Arch. 458 2011 511 523
12. E. Moroşan, M.S. Mihailovici, S.E. Giuşcə, E. Cojocaru, E.R. Avədənei, and I.D. Cəruntu Hepatic steatosis background in chronic hepatitis B and C - significance of similarities and differences Rom. J. Morphol. Embryol. 55 2014 1041 1047
13. M. Blachier, H. Leleu, M. Peck-Radosavljevic, D.C. Valla, and F. Roudot-Thoraval The burden of liver disease in Europe: a review of available epidemiological data J. Hepatol. 58 2013 593 608
14. J.E. Everhart, and C.E. Ruhl Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas Gastroenterology 136 2009 1134 1144
15. Z.V. Fong, and K.K. Tanabe The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review Cancer 120 2014 2824 2838
16. K.E. Corey, and L.M. Kaplan Obesity and liver disease: the epidemic of the twenty-first century Clin. Liver Dis. 18 2014 1 18
17. M. van Agthoven, H.J. Metselaar, H.W. Tilanus, R.A. de Man, J.N. IJzermans, and B.M. Martin van Ineveld A comparison of the costs and effects of liver transplantation for acute and for chronic liver failure Transpl. Int. 14 2001 87 94
18. K. Tauchi-Sato, S. Ozeki, T. Houjou, R. Taguchi, and T. Fujimoto The surface of lipid droplets is a phospholipid monolayer with a unique Fatty Acid composition J. Biol. Chem. 277 2002 44507 44512
19. A.D. Burt, A. Mutton, and C.P. Day Diagnosis and interpretation of steatosis and steatohepatitis Semin. Diagn. Pathol. 15 1998 246 258
20. C.P. Day, and O.F. James Steatohepatitis: a tale of two "hits"? Gastroenterology 114 1998 842 845
21. C.P. Day Pathogenesis of steatohepatitis Best Pract. Res. Clin. Gastroenterol. 16 2002 663 678
22. C.P. Oliveira, J. Faintuch, A. Rascovski, C.K. Furuya, Bastos. MoS, and M. Matsuda Lipid peroxidation in bariatric candidates with nonalcoholic fatty liver disease (NAFLD) - preliminary findings Obes. Surg. 15 2005 502 505
23. L.A. Videla, R. Rodrigo, M. Orellana, V. Fernandez, G. Tapia, and L. Quiñones Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients Clin. Sci. (Lond.) 106 2004 261 268
24. A. Elizondo, J. Araya, R. Rodrigo, C. Signorini, C. Sgherri, and M. Comporti Effects of weight loss on liver and erythrocyte polyunsaturated fatty acid pattern and oxidative stress status in obese patients with non-alcoholic fatty liver disease Biol. Res. 41 2008 59 68
25. P. Pettinelli, A.M. Obregón, and L.A. Videla Molecular mechanisms of steatosis in nonalcoholic fatty liver disease Nutr. Hosp. 26 2011 441 450
26. N. Méndez-Sánchez, M. Arrese, D. Zamora-Valdés, and M. Uribe Current concepts in the pathogenesis of nonalcoholic fatty liver disease Liver Int. 27 2007 423 433
27. H. Cortez-Pinto, M.C. de Moura, and C.P. Day Non-alcoholic steatohepatitis: from cell biology to clinical practice J. Hepatol. 44 2006 197 208
28. P. Almeda-Valdés, D. Cuevas-Ramos, and C.A. Aguilar-Salinas Metabolic syndrome and non-alcoholic fatty liver disease Ann. Hepatol. 8 Suppl 1 2009 S18 S24
29. S.M. Grundy, B. Hansen, S.C. Smith, J.I. Cleeman, R.A. Kahn, and A.H. Association Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management Circulation 109 2004 551 556
30. P. Angulo Nonalcoholic fatty liver disease N. Engl. J. Med. 346 2002 1221 1231
31. E.M. Brunt Pathology of nonalcoholic fatty liver disease Nat. Rev. Gastroenterol. Hepatol. 7 2010 195 203
32. J.A. Shayman, and A. Abe Drug induced phospholipidosis: an acquired lysosomal storage disorder Biochim. Biophys. Acta 1831 2013 602 611
33. J.K. Dyson, Q.M. Anstee, and S. McPherson Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging Frontline Gastroenterol. 5 2014 211 218
34. D. Felker, A. Lynn, S. Wang, and D.E. Johnson Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity Expert Rev. Clin. Pharmacol. 7 2014 211 218
35. T. Lempérière Brief history of the development of valproate in bipolar disorders Encephale 27 2001 365 372
36. C.L. Bowden Valproate Bipolar Disord. 5 2003 189 202
37. J.R. Calabrese, and G.A. Delucchi Phenomenology of rapid cycling manic depression and its treatment with valproate J. Clin. Psychiatry 50 Suppl 1989 30 34
38. G. Erenberg, A.D. Rothner, C.E. Henry, and R.P. Cruse Valproic acid in the treatment of intractable absence seizures in children: a single-blind clinical and quantitative EEG study Am. J. Dis. Child 136 1982 526 529
39. G. Coppola, G. Auricchio, R. Federico, M. Carotenuto, and A. Pascotto Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study Epilepsia 45 2004 1049 1053
40. J.C. Dean, and J.K. Penry Valproate monotherapy in 30 patients with partial seizures Epilepsia 29 1988 140 144
41. S. Calleja, J. Salas-Puig, R. Ribacoba, and C.H. Lahoz Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate Seizure 10 2001 424 427
42. C.J. Phiel, F. Zhang, E.Y. Huang, M.G. Guenther, M.A. Lazar, and P.S. Klein Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen J. Biol. Chem. 276 2001 36734 36741
43. R.M. Nanau, and M.G. Neuman Adverse drug reactions induced by valproic acid Clin. Biochem. 46 2013 1323 1338
44. D.M. Turnbull, A.J. Bone, K. Bartlett, P.P. Koundakjian, and H.S. Sherratt The effects of valproate on intermediary metabolism in isolated rat hepatocytes and intact rats Biochem. Pharmacol. 32 1983 1887 1892
45. S. Ponchaut, F. van Hoof, and K. Veitch In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions Biochem. Pharmacol. 43 1992 2435 2442
46. S.M. Bjorge, and T.A. Baillie Inhibition of medium-chain fatty acid beta-oxidation in vitro by valproic acid and its unsaturated metabolite, 2-n-propyl-4-pentenoic acid Biochem. Biophys. Res. Commun. 132 1985 245 252
47. M.H. Lee, M. Kim, B.H. Lee, J.H. Kim, K.S. Kang, and H.L. Kim Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver Toxicol. Appl. Pharmacol. 226 2008 271 284
48. A.C. Knapp, L. Todesco, K. Beier, L. Terracciano, H. Sägesser, and J. Reichen Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores J. Pharmacol. Exp. Ther. 324 2008 568 575
49. E. Kingsley, P. Gray, K.G. Tolman, and R. Tweedale The toxicity of metabolites of sodium valproate in cultured hepatocytes J. Clin. Pharmacol. 23 1983 178 185
50. G.R. Granneman, S.I. Wang, J.W. Kesterson, and J.M. Machinist The hepatotoxicity of valproic acid and its metabolites in rats. II. Intermediary and valproic acid metabolism Hepatology 4 1984 1153 1158
51. J.W. Kesterson, G.R. Granneman, and J.M. Machinist The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies Hepatology 4 1984 1143 1152
52. K. Kassahun, K. Farrell, and F. Abbott Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans Drug Metab. Dispos. 19 1991 525 535
53. A.J. Sadeque, M.B. Fisher, K.R. Korzekwa, F.J. Gonzalez, and A.E. Rettie Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid J. Pharmacol. Exp. Ther. 283 1997 698 703
54. J.J. Lemasters, A.L. Nieminen, T. Qian, L.C. Trost, S.P. Elmore, and Y. Nishimura The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy Biochim. Biophys. Acta 1366 1998 177 196
55. C.C. Aires, L. Ijlst, F. Stet, C. Prip-Buus, I.T. de Almeida, and M. Duran Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis Biochem. Pharmacol. 79 2010 792 799
56. T.E. Van Cott, K.S. Yehle, S.K. DeCrane, and J.R. Thorlton Amiodarone-induced pulmonary toxicity: case study with syndrome analysis Heart Lung 42 2013 262 266
57. B.E. Stähli, and S. Schwab Amiodarone-induced skin hyperpigmentation QJM 104 2011 723 724
58. C. Preda, A.C. Aprotosoaie, A. Petris, and I.I. Costache Amiodarone-induced thyroid dysfunction-clinical picture. Study on 215 cases Rev. Med. Chir. Soc. Med. Nat. Iasi 118 2014 359 363
59. J.G. Li, T.C. Yang, D.M. Yu, and T.H. Ren Fatal acute liver failure after intravenous amiodarone administration J. Formos. Med. Assoc. 2013
60. B. Fromenty, C. Fisch, G. Labbe, C. Degott, D. Deschamps, and A. Berson Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice J. Pharmacol. Exp. Ther. 255 1990 1371 1376
61. K. Kumar, and P.J. Zimetbaum Antiarrhythmic drugs 2013: state of the art Curr. Cardiol. Rep. 15 2013 410
62. S.R. Punnam, S.K. Goyal, V.P. Kotaru, A.R. Pachika, G.S. Abela, and R.K. Thakur Amiodarone - a 'broad spectrum' antiarrhythmic drug Cardiovasc. Hematol. Disord. Drug Targets 10 2010 73 81
63. T.C. McCarthy, P.T. Pollak, E.A. Hanniman, and C.J. Sinal Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation J. Pharmacol. Exp. Ther. 311 2004 864 873
64. D. Deschamps, V. DeBeco, C. Fisch, B. Fromenty, A. Guillouzo, and D. Pessayre Inhibition by perhexiline of oxidative phosphorylation and the beta-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions Hepatology 19 1994 948 961
65. G. Varbiro, A. Toth, A. Tapodi, B. Veres, B. Sumegi, and F. Gallyas Concentration dependent mitochondrial effect of amiodarone Biochem. Pharmacol. 65 2003 1115 1128
66. J.R. Wetterau, M.C. Lin, and H. Jamil Microsomal triglyceride transfer protein Biochim. Biophys. Acta 1345 1997 136 150
67. A. Felser, K. Blum, P.W. Lindinger, J. Bouitbir, and S. Krähenbühl Mechanisms of hepatocellular toxicity associated with dronedarone-a comparison to amiodarone Toxicol. Sci. 131 2013 480 490
68. I. Chopra, and M. Roberts Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance Microbiol. Mol. Biol. Rev. 65 2001 232 260 second page, table of contents
69. M. Thiim, and L.S. Friedman Hepatotoxicity of antibiotics and antifungals Clin. Liver. Dis. 7 2003 381-99, vi-vii
70. T.J. Ford, and J.F. Dillon Minocycline hepatitis Eur. J. Gastroenterol. Hepatol. 20 2008 796 799
71. H.Q. Yin, M. Kim, J.H. Kim, G. Kong, M.O. Lee, and K.S. Kang Hepatic gene expression profiling and lipid homeostasis in mice exposed to steatogenic drug, tetracycline Toxicol. Sci. 94 2006 206 216
72. H.Y. Yu, B.L. Wang, J. Zhao, X.M. Yao, Y. Gu, and Y. Li Protective effect of bicyclol on tetracycline-induced fatty liver in mice Toxicology 261 2009 112 118
73. L.J. Journey, and M.N. Goldstein The effect of terramycin on the fine structure of HeLa cell mitochondria Cancer Res. 23 1963 551 554
74. H.G. Du Buy, and J.L. Showacre Selective localization of tetracycline in mitochondria of living cells Science 133 1961 196 197
75. J.C. Schultz, J.S. Adamson, W.W. Workman, and T.D. Norman Fatal liver disease after intravenous administration of tetracycline in high dosage N. Engl. J. Med. 269 1963 999 1004
76. R.L. Peters, H.A. Edmondson, W.P. Mikkelsen, and D. Tatter Tetracycline-induced fatty liver in nonpregnant patients. A report of six cases Am. J. Surg. 113 1967 622 632
77. M.O. Griffin, E. Fricovsky, G. Ceballos, and F. Villarreal Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature Am. J. Physiol. Cell Physiol. 299 2010 C539 C548
78. J. Chang, T.J. Powles, S.E. Ashley, R.K. Gregory, V.A. Tidy, and J.G. Treleaven The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study Ann. Oncol. 7 1996 671 675
79. B.D. Bradbury, T.L. Lash, J.A. Kaye, and S.S. Jick Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina Cancer 103 2005 1114 1121
80. A.K. Shiau, D. Barstad, P.M. Loria, L. Cheng, P.J. Kushner, and D.A. Agard The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen Cell 95 1998 927 937
81. (EBCTCG) EBCTCG Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
82. M. Nishino, K. Hayakawa, Y. Nakamura, T. Morimoto, and S. Mukaihara Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy AJR Am. J. Roentgenol. 180 2003 129 134
83. Y. Murata, Y. Ogawa, T. Saibara, A. Nishioka, Y. Fujiwara, and M. Fukumoto Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients Oncol. Rep. 7 2000 1299 1304
84. K.A. Oien, D. Moffat, G.W. Curry, J. Dickson, T. Habeshaw, and P.R. Mills Cirrhosis with steatohepatitis after adjuvant tamoxifen Lancet 353 1999 36 37
85. M.H. Lee, J.W. Kim, J.H. Kim, K.S. Kang, G. Kong, and M.O. Lee Gene expression profiling of murine hepatic steatosis induced by tamoxifen Toxicol. Lett. 199 2010 416 424
86. O.A. Gudbrandsen, T.H. Rost, and R.K. Berge Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver J. Lipid Res. 47 2006 2223 2232
87. C.M. Cardoso, J.B. Custódio, L.M. Almeida, and A.J. Moreno Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency Toxicol. Appl. Pharmacol. 176 2001 145 152
88. C. Tuquet, J. Dupont, A. Mesneau, and J. Roussaux Effects of tamoxifen on the electron transport chain of isolated rat liver mitochondria Cell Biol. Toxicol. 16 2000 207 219
89. K.M. Starko, C.G. Ray, L.B. Dominguez, W.L. Stromberg, and D.F. Woodall Reye's syndrome and salicylate use Pediatrics 66 1980 859 864
90. R.D. Reye, G. Morgan, and J. Baral Encephalopathy and fatty degeneration of the viscera. A disease entity in childhood Lancet 2 1963 749 752
91. T.Y. Segalman, and C.P. Lee Reye's syndrome: plasma-induced alterations in mitochondrial structure and function Arch. Biochem. Biophys. 214 1982 522 530
92. K. You Salicylate and mitochondrial injury in Reye's syndrome Science 221 1983 163 165
93. M.E. Martens, C.H. Chang, and C.P. Lee Reye's syndrome: mitochondrial swelling and Ca2+ release induced by Reye's plasma, allantoin, and salicylate Arch. Biochem. Biophys. 244 1986 773 786
94. G.S. Browne, C. Nelson, T. Nguyen, B.A. Ellis, R.O. Day, and K.M. Williams Stereoselective and substrate-dependent inhibition of hepatic mitochondria beta-oxidation and oxidative phosphorylation by the non-steroidal anti-inflammatory drugs ibuprofen, flurbiprofen, and ketorolac Biochem. Pharmacol. 57 1999 837 844
95. E. Freneaux, B. Fromenty, A. Berson, G. Labbe, C. Degott, and P. Letteron Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial beta-oxidation of fatty acids J. Pharmacol. Exp. Ther. 255 1990 529 535
96. P. Lettéron, A. Sutton, A. Mansouri, B. Fromenty, and D. Pessayre Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice Hepatology 38 2003 133 140
97. A. Berson, S. Cazanave, V. Descatoire, M. Tinel, A. Grodet, and C. Wolf The anti-inflammatory drug, nimesulide (4-nitro-2-phenoxymethane-sulfoanilide), uncouples mitochondria and induces mitochondrial permeability transition in human hepatoma cells: protection by albumin J. Pharmacol. Exp. Ther. 318 2006 444 454
98. J.P. Panatto, I.C. Jeremias, G.K. Ferreira, A.C. Ramos, N. Rochi, and C.L. Gonçalves Inhibition of mitochondrial respiratory chain in the brain of rats after hepatic failure induced by acetaminophen Mol. Cell. Biochem. 350 2011 149 154
99. M.R. McGill, M.R. Sharpe, C.D. Williams, M. Taha, S.C. Curry, and H. Jaeschke The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation J. Clin. Invest. 122 2012 1574 1583
100. Y. Masubuchi, C. Suda, and T. Horie Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice J. Hepatol. 42 2005 110 116
101. C. Roubille, V. Richer, T. Starnino, C. McCourt, A. McFarlane, and P. Fleming The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis Ann. Rheum. Dis. 2015
102. A. Swaminath, R. Taunk, and G. Lawlor Use of methotrexate in inflammatory bowel disease in 2014: a user's guide World J. Gastrointest. Pharmacol. Ther. 5 2014 113 121
103. J. König, A. Seithel, U. Gradhand, and M.F. Fromm Pharmacogenomics of human OATP transporters Naunyn. Schmiedebergs Arch. Pharmacol. 372 2006 432 443
104. V. Kolli, K. Natarajan, B. Isaac, D. Selvakumar, and P. Abraham Mitochondrial dysfunction and respiratory chain defects in a rodent model of methotrexate-induced enteritis Hum. Exp. Toxicol. 33 2014 1051 1065
105. R. Ramachandran, and S. Kakar Histological patterns in drug-induced liver disease J. Clin. Pathol. 62 2009 481 492
106. J.N. Vauthey, T.M. Pawlik, D. Ribero, T.T. Wu, D. Zorzi, and P.M. Hoff Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases J. Clin. Oncol. 24 2006 2065 2072
107. T. Le Dinh, E. Freneaux, G. Labbe, P. Letteron, C. Degott, and J. Geneve Amineptine, a tricyclic antidepressant, inhibits the mitochondrial oxidation of fatty acids and produces microvesicular steatosis of the liver in mice J. Pharmacol. Exp. Ther 247 1988 745 750
108. B. Fromenty, E. Freneaux, G. Labbe, D. Deschamps, D. Larrey, and P. Letteron Tianeptine, a new tricyclic antidepressant metabolized by beta-oxidation of its heptanoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in mice Biochem. Pharmacol. 38 1989 3743 3751
109. A. Igoudjil, J. Massart, K. Begriche, V. Descatoire, M.A. Robin, and B. Fromenty High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes Toxicol. In Vitro 22 2008 887 898
110. U.A. Walker, J. Bäuerle, M. Laguno, J. Murillas, S. Mauss, and G. Schmutz Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine Hepatology 39 2004 311 317
111. J.A. Kennedy, S.A. Unger, and J.D. Horowitz Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone Biochem. Pharmacol. 52 1996 273 280
112. D. Lewis, H.C. Wainwright, M.C. Kew, S. Zwi, and C. Isaacson Liver damage associated with perhexiline maleate Gut 20 1979 186 189
113. S. Jazcilevich, and S. Villa-Treviño Induction of fatty liver in the rat after cycloheximide administration Lab. Invest. 23 1970 590 594
114. J.A. García-Sáinz, R. Hernández-Muñoz, A. Santamaría, and V.C. de Sánchez Mechanism of the fatty liver induced by cycloheximide and its reversibility by adenosine Biochem. Pharmacol. 28 1979 1409 1413
115. H. Bar-On, O. Stein, and Y. Stein Mulitiple effects of cycloheximide on the metabolism of triglycerides in the liver of male and female rats Biochim. Biophys. Acta 270 1972 444 452
116. M. Murakami, K. Bessho, S. Mushiake, H. Kondou, Y. Miyoshi, and K. Ozono Major role of apolipoprotein B in cycloheximide-induced acute hepatic steatosis in mice Hepatol. Res. 41 2011 446 454
117. T. Mach, and A. Janik The effect of prolonged administration of disulfiram alone or in combination with ethanol on some indices of lipid metabolism in the blood serum and hepatic tissue of the rat Pol. J. Pharmacol. Pharm. 32 1980 327 332
118. M.Y. Balakirev, and G. Zimmer Mitochondrial injury by disulfiram: two different mechanisms of the mitochondrial permeability transition Chem. Biol. Interact. 138 2001 299 311
119. M.A. Kuroda, and A. Cuéllar Deleterious effects of disulfiram on the respiratory electron transport system of liver mitochondria Int. J. Biochem. 25 1993 87 91
120. D.M. Horn, L.A. Neeb, J.M. Colacino, and F.C. Richardson Fialuridine is phosphorylated and inhibits DNA synthesis in isolated rat hepatic mitochondria Antiviral. Res. 34 1997 71 74
121. A. Berson, V. Descatoire, A. Sutton, D. Fau, B. Maulny, and N. Vadrot Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation J. Pharmacol. Exp. Ther. 299 2001 793 800
122. A. Berson, L. Schmets, C. Fisch, D. Fau, C. Wolf, and B. Fromenty Inhibition by nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this antiandrogen J. Pharmacol. Exp. Ther. 270 1994 167 176
123. L.I. Rachek, L.V. Yuzefovych, S.P. Ledoux, N.L. Julie, and G.L. Wilson Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes Toxicol. Appl. Pharmacol. 240 2009 348 354
124. T. Okuda, M. Norioka, Y. Shitara, and T. Horie Multiple mechanisms underlying troglitazone-induced mitochondrial permeability transition Toxicol. Appl. Pharmacol. 248 2010 242 248
125. T. Melo, R.A. Videira, S. André, E. Maciel, C.S. Francisco, and A.M. Oliveira-Campos Tacrine and its analogues impair mitochondrial function and bioenergetics: a lipidomic analysis in rat brain J. Neurochem. 120 2012 998 1013
126. A. Mansouri, D. Haouzi, V. Descatoire, C. Demeilliers, A. Sutton, and N. Vadrot Tacrine inhibits topoisomerases and DNA synthesis to cause mitochondrial DNA depletion and apoptosis in mouse liver Hepatology 38 2003 715 725
127. S. Tanaka, H. Shimonaka, T. Tanahashi, H. Uematsu, M. Yamamoto, and K. Kawai Et al. The effect of buprenorphine on oxidative phosphorylation in isolated rat liver mitochondria Masui 34 1985 1456 1462
128. C. Feo, and E. Garçon Study of steatosis induced in the rat by orotic acid Biomedicine 19 1973 61 64
129. W.V. Zhang, I. Ramzan, and M. Murray Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis J. Pharmacol. Exp. Ther. 322 2007 770 777
130. T.O. Hammes, G.L. Pedroso, C.R. Hartmann, T.D. Escobar, L.B. Fracasso, and D.P. da Rosa The effect of taurine on hepatic steatosis induced by thioacetamide in zebrafish (Danio rerio) Dig. Dis. Sci. 57 2012 675 682
131. Y. Takahashi, Y. Soejima, and T. Fukusato Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis World J. Gastroenterol. 18 2012 2300 2308
132. G. Kanuri, and I. Bergheim In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD) Int. J. Mol. Sci. 14 2013 11963 11980
133. A.A. Nanji Role of different dietary fatty acids in the pathogenesis of experimental alcoholic liver disease Alcohol 34 2004 21 25
134. S.A. van den Berg, B. Guigas, S. Bijland, M. Ouwens, P.J. Voshol, and R.R. Frants High levels of dietary stearate promote adiposity and deteriorate hepatic insulin sensitivity Nutr. Metab. (Lond.) 7 2010 24
135. Q.M. Anstee, and R.D. Goldin Mouse models in non-alcoholic fatty liver disease and steatohepatitis research Int. J. Exp. Pathol. 87 2006 1 16
136. I.A. Leclercq, G.C. Farrell, J. Field, D.R. Bell, F.J. Gonzalez, and G.R. Robertson CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis J. Clin. Invest. 105 2000 1067 1075
137. C.Z. Larter, M.M. Yeh, J. Williams, K.S. Bell-Anderson, and G.C. Farrell MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes J. Hepatol. 49 2008 407 416
138. M.E. Rinella, M.S. Elias, R.R. Smolak, T. Fu, J. Borensztajn, and R.M. Green Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet J. Lipid Res. 49 2008 1068 1076
139. J.G. Fan, and L. Qiao Commonly used animal models of non-alcoholic steatohepatitis Hepatobiliary Pancreat. Dis. Int. 8 2009 233 240
140. S. De Minicis, L. Agostinelli, C. Rychlicki, G.P. Sorice, S. Saccomanno, and C. Candelaresi HCC development is associated to peripheral insulin resistance in a mouse model of NASH PLoS One 9 2014 e97136
141. I.P. Pogribny, V.P. Tryndyak, L. Muskhelishvili, I. Rusyn, and S.A. Ross Methyl deficiency, alterations in global histone modifications, and carcinogenesis J. Nutr. 137 2007 216S 222S
142. I.P. Pogribny, V.P. Tryndyak, T.V. Bagnyukova, S. Melnyk, B. Montgomery, and S.A. Ross Hepatic epigenetic phenotype predetermines individual susceptibility to hepatic steatosis in mice fed a lipogenic methyl-deficient diet J. Hepatol. 51 2009 176 186
143. Z. Ackerman, M. Oron-Herman, M. Grozovski, T. Rosenthal, O. Pappo, and G. Link Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction Hypertension 45 2005 1012 1018
144. A. Spruss, G. Kanuri, S. Wagnerberger, S. Haub, S.C. Bischoff, and I. Bergheim Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice Hepatology 50 2009 1094-04
145. T. Kawasaki, K. Igarashi, T. Koeda, K. Sugimoto, K. Nakagawa, and S. Hayashi Rats fed fructose-enriched diets have characteristics of nonalcoholic hepatic steatosis J. Nutr. 139 2009 2067 2071
146. A. Schultz, D. Neil, M.B. Aguila, and C.A. Mandarim-de-Lacerda Hepatic adverse effects of fructose consumption independent of overweight/obesity Int. J. Mol. Sci. 14 2013 21873 21886
147. M. Charlton, A. Krishnan, K. Viker, S. Sanderson, S. Cazanave, and A. McConico Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition Am. J. Physiol. Gastrointest. Liver Physiol. 301 2011 G825 G834
148. S. Lopez, B. Bermudez, S. Montserrat-de la Paz, S. Jaramillo, L.M. Varela, and A. Ortega-Gomez Membrane composition and dynamics: a target of bioactive virgin olive oil constituents Biochim. Biophys. Acta 1838 2014 1638 1656
149. A. Baylin, R. Deka, J. Tuitele, S. Viali, D.E. Weeks, and S.T. McGarvey INSIG2 variants, dietary patterns and metabolic risk in Samoa Eur. J. Clin. Nutr. 67 2013 101 107
150. A. Kotronen, H. Yki-Järvinen, K. Sevastianova, R. Bergholm, A. Hakkarainen, and K.H. Pietiläinen Comparison of the relative contributions of intra-abdominal and liver fat to components of the metabolic syndrome Obesity (Silver Spring) 19 2011 23 28
151. A. Andersson, C. Nälsén, S. Tengblad, and B. Vessby Fatty acid composition of skeletal muscle reflects dietary fat composition in humans Am. J. Clin. Nutr. 76 2002 1222 1229
152. G. Rocquelin, L. Guenot, P.O. Astorg, and M. David Phospholipid content and fatty acid composition of human heart Lipids 24 1989 775 780
153. G. Bahrami, M. Masoumi, and Z. Rahimi Co-existence of fatty acids changes in aorta artery and adipose tissue; comparison between CAD and non CAD patients J. Thromb. Thrombolysis 27 2009 185 190
154. T. Fraser, H. Tayler, and S. Love Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease Neurochem. Res. 35 2010 503 513
155. J. Guest, M. Garg, A. Bilgin, and R. Grant Relationship between central and peripheral fatty acids in humans Lipids Health Dis. 12 2013 79
156. J. Araya, R. Rodrigo, L.A. Videla, L. Thielemann, M. Orellana, and P. Pettinelli Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease Clin. Sci. (Lond.) 106 2004 635 643
157. G. Martin, M. Nemoto, L. Gelman, S. Geffroy, J. Najib, and J.C. Fruchart The human fatty acid transport protein-1 (SLC27A1; FATP-1) cDNA and gene: organization, chromosomal localization, and expression Genomics 66 2000 296 304
158. F. Ge, S. Zhou, C. Hu, H. Lobdell, and P.D. Berk Insulin- and leptin-regulated fatty acid uptake plays a key causal role in hepatic steatosis in mice with intact leptin signaling but not in ob/ob or db/db mice Am. J. Physiol. Gastrointest. Liver Physiol. 299 2010 G855 G866
159. S.L. Zhou, D. Stump, D. Sorrentino, B.J. Potter, and P.D. Berk Adipocyte differentiation of 3T3-L1 cells involves augmented expression of a 43-kDa plasma membrane fatty acid-binding protein J. Biol. Chem. 267 1992 14456 14461
160. S.L. Zhou, D. Stump, C.L. Kiang, L.M. Isola, and P.D. Berk Mitochondrial aspartate aminotransferase expressed on the surface of 3T3-L1 adipocytes mediates saturable fatty acid uptake Proc. Soc. Exp. Biol. Med. 208 1995 263 270
161. B.L. Trigatti, R.G. Anderson, and G.E. Gerber Identification of caveolin-1 as a fatty acid binding protein Biochem. Biophys. Res. Commun. 255 1999 34 39
162. D. Pessayre, A. Mansouri, A. Berson, and B. Fromenty Mitochondrial involvement in drug-induced liver injury Handb. Exp. Pharmacol. 2010 311 365
163. A. De Gottardi, M. Vinciguerra, A. Sgroi, M. Moukil, F. Ravier-Dall'Antonia, and V. Pazienza Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes Lab. Invest. 87 2007 792 806
164. N. Anderson, and J. Borlak Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis Pharmacol. Rev. 60 2008 311 357
165. K.L. Donnelly, C.I. Smith, S.J. Schwarzenberg, J. Jessurun, M.D. Boldt, and E.J. Parks Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease J. Clin. Invest. 115 2005 1343 1351
166. M.W. Bradbury Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis Am. J. Physiol. Gastrointest. Liver Physiol. 290 2006 G194 G198
167. J. Niklas, A. Bonin, S. Mangin, J. Bucher, S. Kopacz, and M. Matz-Soja Central energy metabolism remains robust in acute steatotic hepatocytes challenged by a high free fatty acid load BMB Rep. 45 2012 396 401
168. W. Cui, S.L. Chen, and K.Q. Hu Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells Am. J. Transl. Res. 2 2010 95 104
169. D. Zhang, L. Xie, G. Jia, S. Cai, B. Ji, and Y. Liu Comparative study on antioxidant capacity of flavonoids and their inhibitory effects on oleic acid-induced hepatic steatosis in vitro Eur. J. Med. Chem. 46 2011 4548 4558
170. N. Ziamajidi, S. Khaghani, G. Hassanzadeh, S. Vardasbi, S. Ahmadian, and A. Nowrouzi Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1 Food Chem. Toxicol. 58 2013 198 209
171. R. Kirsch, V. Clarkson, E.G. Shephard, D.A. Marais, M.A. Jaffer, and V.E. Woodburne Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies J. Gastroenterol. Hepatol. 18 2003 1272 1282
172. S. Stöppeler, D. Palmes, M. Fehr, J.P. Hölzen, A. Zibert, and R. Siaj Gender and strain-specific differences in the development of steatosis in rats Lab. Anim. 47 2013 43 52
173. P. Letteron, B. Fromenty, B. Terris, C. Degott, and D. Pessayre Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice J. Hepatol. 24 1996 200 208
174. V. Tong, X.W. Teng, T.K. Chang, and F.S. Abbott Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats Toxicol. Sci. 86 2005 427 435
175. M.A. Abdel-Dayem, A.A. Elmarakby, A.A. Abdel-Aziz, C. Pye, S.A. Said, and A.M. El-Mowafy Valproate-induced liver injury: modulation by the omega-3 fatty acid DHA proposes a novel anticonvulsant regimen Drugs R D 14 2014 85 94
176. M.H. Lee, I. Hong, M. Kim, B.H. Lee, J.H. Kim, and K.S. Kang Gene expression profiles of murine fatty liver induced by the administration of valproic acid Toxicol. Appl. Pharmacol. 220 2007 45 59
177. S.K. Natarajan, C.E. Eapen, A.B. Pullimood, and K.A. Balasubramanian Oxidative stress in experimental liver microvesicular steatosis: role of mitochondria and peroxisomes J. Gastroenterol. Hepatol. 21 2006 1240 1249
178. M.L. Costa, R.C. Lima-Júnior, K.S. Aragão, R.P. Medeiros, R.D. Marques-Neto, and Grassi L. de Sá Chemotherapy-associated steatohepatitis induced by irinotecan: a novel animal model Cancer Chemother. Pharmacol. 74 2014 711 720
179. S. Nishio, Y. Gibert, L. Bernard, F. Brunet, G. Triqueneaux, and V. Laudet Adiponectin and adiponectin receptor genes are coexpressed during zebrafish embryogenesis and regulated by food deprivation Dev. Dyn. 237 2008 1682 1690
180. A. Ibabe, M. Grabenbauer, E. Baumgart, H.D. Fahimi, and M.P. Cajaraville Expression of peroxisome proliferator-activated receptors in zebrafish (Danio rerio) Histochem. Cell Biol. 118 2002 231 239
181. A.A. Amali, R.D. Rekha, C.J. Lin, W.L. Wang, H.Y. Gong, and G.M. Her Thioacetamide induced liver damage in zebrafish embryo as a disease model for steatohepatitis J. Biomed. Sci. 13 2006 225 232
182. D.L. Howarth, C. Yin, K. Yeh, and K.C. Sadler Defining hepatic dysfunction parameters in two models of fatty liver disease in zebrafish larvae Zebrafish 10 2013 199 210
183. T. Tainaka, Y. Shimada, J. Kuroyanagi, L. Zang, T. Oka, and Y. Nishimura Transcriptome analysis of anti-fatty liver action by Campari tomato using a zebrafish diet-induced obesity model Nutr. Metab. (Lond.) 8 2011 88
184. M. Hiramitsu, Y. Shimada, J. Kuroyanagi, T. Inoue, T. Katagiri, and L. Zang Eriocitrin ameliorates diet-induced hepatic steatosis with activation of mitochondrial biogenesis Sci. Rep. 4 2014 3708
185. V. Sapp, L. Gaffney, S.F. EauClaire, and R.P. Matthews Fructose leads to hepatic steatosis in zebrafish that is reversed by mechanistic target of rapamycin (mTOR) inhibition Hepatology 60 2014 1581 1592
186. P. Lindström The physiology of obese-hyperglycemic mice [Ob/ob mice] Sci. World J. 7 2007 666 685
187. S.Q. Yang, H.Z. Lin, M.D. Lane, M. Clemens, and A.M. Diehl Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis Proc. Natl. Acad. Sci. U. S. A. 94 1997 2557 2562
188. M. Wortham, L. He, M. Gyamfi, B.L. Copple, and Y.J. Wan The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet Dig. Dis. Sci. 53 2008 2761 2774
189. S.R. Ross, R.A. Graves, and B.M. Spiegelman Targeted expression of a toxin gene to adipose tissue: transgenic mice resistant to obesity Genes Dev. 7 1993 1318 1324
190. H. Shimano, J.D. Horton, R.E. Hammer, I. Shimomura, M.S. Brown, and J.L. Goldstein Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a J. Clin. Invest. 98 1996 1575 1584
191. H. Shimano, N. Yahagi, M. Amemiya-Kudo, A.H. Hasty, J. Osuga, and Y. Tamura Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes J. Biol. Chem. 274 1999 35832 35839
192. I. Shimomura, R.E. Hammer, S. Ikemoto, M.S. Brown, and J.L. Goldstein Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy Nature 401 1999 73 76
193. M. Febbraio, N.A. Abumrad, D.P. Hajjar, K. Sharma, W. Cheng, and S.F. Pearce A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism J. Biol. Chem. 274 1999 19055 19062
194. Y. Simon, S.M. Kessler, K. Gemperlein, R.M. Bohle, R. Müller, and J. Haybaeck Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis World J. Gastroenterol. 20 2014 17839 17850
195. M. Lu, R.M. Nakamura, E.D. Dent, J.Y. Zhang, F.C. Nielsen, and J. Christiansen Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis Am. J. Pathol. 159 2001 945 953
196. Y. Simon, S.M. Kessler, R.M. Bohle, J. Haybaeck, and A.K. Kiemer The insulin-like growth factor 2 (IGF2) mRNA-binding protein p62/IGF2BP2-2 as a promoter of NAFLD and HCC? Gut 63 2014 861 863
197. E. Tybl, F.D. Shi, S.M. Kessler, S. Tierling, J. Walter, and R.M. Bohle Overexpression of the IGF2-mRNA binding protein p62 in transgenic mice induces a steatotic phenotype J. Hepatol. 54 2011 994 1001
198. P. Dongiovanni, B. Donati, R. Fares, R. Lombardi, R.M. Mancina, and S. Romeo PNPLA3 I148M polymorphism and progressive liver disease World J. Gastroenterol. 19 2013 6969 6978
199. E. Smagris, S. BasuRay, J. Li, Y. Huang, K.M. Lai, and J. Gromada Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis Hepatology 61 2015 108 118
200. S.C. Garcia Caraballo, T.M. Comhair, C.H. Dejong, W.H. Lamers, and S.E. Köhler A high-protein diet is anti-steatotic and has no pro-inflammatory side effects in dyslipidaemic APOE2 knock-in mice Br. J. Nutr. 112 2014 1251 1265
201. J.M. Nussbaum, L.J. Liu, S.A. Hasan, M. Schaub, A. McClendon, and D.Y. Stainier Homeostatic generation of reactive oxygen species protects the zebrafish liver from steatosis Hepatology 58 2013 1326 1338
202. W.Y. Pai, C.C. Hsu, C.Y. Lai, T.Z. Chang, Y.L. Tsai, and G.M. Her Cannabinoid receptor 1 promotes hepatic lipid accumulation and lipotoxicity through the induction of SREBP-1c expression in zebrafish Transgenic Res. 22 2013 823 838
203. G.M. Her, W.Y. Pai, C.Y. Lai, Y.W. Hsieh, and H.W. Pang Ubiquitous transcription factor YY1 promotes zebrafish liver steatosis and lipotoxicity by inhibiting CHOP-10 expression Biochim. Biophys. Acta 1831 2013 1037 1051
204. C. Ji, and N. Kaplowitz ER stress: can the liver cope? J. Hepatol. 45 2006 321 333
205. P.C. Thakur, C. Stuckenholz, M.R. Rivera, J.M. Davison, J.K. Yao, and A. Amsterdam Lack of de novo phosphatidylinositol synthesis leads to endoplasmic reticulum stress and hepatic steatosis in cdipt-deficient zebrafish Hepatology 54 2011 452 462
206. P. Papeleu, T. Vanhaecke, T. Henkens, G. Elaut, M. Vinken, and S. Snykers Isolation of rat hepatocytes Methods Mol. Biol. 320 2006 229 237
207. Y. Tang, Z. Bian, L. Zhao, Y. Liu, S. Liang, and Q. Wang Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease Clin. Exp. Immunol. 166 2011 281 290
208. A. De Gottardi, L. Spahr, F. Ravier-Dall'Antonia, and A. Hadengue Cannabinoid receptor 1 and 2 agonists increase lipid accumulation in hepatocytes Liver Int. 30 2010 1482 1489
209. M.J. Gómez-Lechón, M.T. Donato, A. Martínez-Romero, N. Jiménez, J.V. Castell, and J.E. O'Connor A human hepatocellular in vitro model to investigate steatosis Chem. Biol. Interact. 165 2007 106 116
210. H. Fujimura, N. Murakami, M. Kurabe, and W. Toriumi In vitro assay for drug-induced hepatosteatosis using rat primary hepatocytes, a fluorescent lipid analog and gene expression analysis J. Appl. Toxicol. 29 2009 356 363
211. C. Guguen-Guillouzo, and A. Guillouzo General review on in vitro hepatocyte models and their applications Methods Mol. Biol. 640 2010 1 40
212. M.T. Donato, N. Jiménez, A. Serralta, J. Mir, J.V. Castell, and M.J. Gómez-Lechón Effects of steatosis on drug-metabolizing capability of primary human hepatocytes Toxicol. In Vitro 21 2007 271 276
213. Y. Lin, M.J. Smit, R. Havinga, H.J. Verkade, R.J. Vonk, and F. Kuipers Differential effects of eicosapentaenoic acid on glycerolipid and apolipoprotein B metabolism in primary human hepatocytes compared to HepG2 cells and primary rat hepatocytes Biochim. Biophys. Acta 1256 1995 88 96
214. M.T. Donato, R. Jover, and M.J. Gómez-Lechón Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering Curr. Drug Metab. 14 2013 946 968
215. B.B. Knowles, C.C. Howe, and D.P. Aden Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen Science 209 1980 497 499
216. N. Dashti, and G. Wolfbauer Secretion of lipids, apolipoproteins, and lipoproteins by human hepatoma cell line, HepG2: effects of oleic acid and insulin J. Lipid Res. 28 1987 423 436
217. X. Shan, Y. Miao, R. Fan, C. Song, G. Wu, and Z. Wan Suppression of Grb2 expression improved hepatic steatosis, oxidative stress, and apoptosis induced by palmitic acid in vitro partly through insulin signaling alteration In Vitro Cell. Dev. Biol. Anim. 49 2013 576 582
218. F. Zhao, P. Xie, J. Jiang, L. Zhang, W. An, and Y. Zhan The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro Int. J. Mol. Sci. 15 2014 4019 4030
219. M.C. Garcia, M. Amankwa-Sakyi, and T.J. Flynn Cellular glutathione in fatty liver in vitro models Toxicol. In Vitro 25 2011 1501 1516
220. S. Anthérieu, A. Rogue, B. Fromenty, A. Guillouzo, and M.A. Robin Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells Hepatology 53 2011 1895 1905
221. S. Madec, V. Cerec, E. Plée-Gautier, J. Antoun, D. Glaise, and J.P. Salaun CYP4F3B expression is associated with differentiation of HepaRG human hepatocytes and unaffected by fatty acid overload Drug Metab. Dispos. 39 2011 1987 1996
222. N.C. Chavez-Tapia, N. Rosso, and C. Tiribelli Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease BMC Gastroenterol. 12 2012 20
223. H. Malhi, F.J. Barreyro, H. Isomoto, S.F. Bronk, and G.J. Gores Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity Gut 56 2007 1124 1131
224. S.N. Bhatia, U.J. Balis, M.L. Yarmush, and M. Toner Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells FASEB J. 13 1999 1883 1900
225. P. Krause, F. Saghatolislam, S. Koenig, K. Unthan-Fechner, and I. Probst Maintaining hepatocyte differentiation in vitro through co-culture with hepatic stellate cells In Vitro Cell Dev. Biol. Anim. 45 2009 205 212
226. S.R. Khetani, and S.N. Bhatia Microscale culture of human liver cells for drug development Nat. Biotechnol. 26 2008 120 126
227. P.J. Giraudi, V.J. Barbero Becerra, V. Marin, N.C. Chavez-Tapia, C. Tiribelli, and N. Rosso The importance of the interaction between hepatocyte and hepatic stellate cells in fibrogenesis induced by fatty accumulation Exp. Mol. Pathol. 98 2014 85 92
228. H. Wobser, C. Dorn, T.S. Weiss, T. Amann, C. Bollheimer, and R. Büttner Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells Cell Res. 19 2009 996 1005
229. S.N. Bhatia, M.L. Yarmush, and M. Toner Controlling cell interactions by micropatterning in co-cultures: hepatocytes and 3T3 fibroblasts J. Biomed. Mater. Res. 34 1997 189 199
230. O. Ukairo, C. Kanchagar, A. Moore, J. Shi, J. Gaffney, and S. Aoyama Long-term stability of primary rat hepatocytes in micropatterned cocultures J. Biochem. Mol. Toxicol. 27 2013 204 212
231. S.R. Khetani, C. Kanchagar, O. Ukairo, S. Krzyzewski, A. Moore, and J. Shi Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans Toxicol. Sci. 132 2013 107 117
232. M.D. Davidson, M. Lehrer, and S.R. Khetani Hormone and drug-mediated modulation of glucose metabolism in a microscale model of the human liver Tissue Eng. Part C Methods 2014
233. C. Lin, K.R. Ballinger, and S.R. Khetani The application of engineered liver tissues for novel drug discovery Expert Opin. Drug Discov. 10 2015 519 540
234. P. Godoy, N.J. Hewitt, U. Albrecht, M.E. Andersen, N. Ansari, and S. Bhattacharya Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME Arch. Toxicol. 87 2013 1315 1530
235. N.I. Nativ, G. Yarmush, A. Chen, D. Dong, S.D. Henry, and J.V. Guarrera Rat hepatocyte culture model of macrosteatosis: effect of macrosteatosis induction and reversal on viability and liver-specific function J. Hepatol. 59 2013 1307 1314
236. C. Parmentier, G.L. Truisi, K. Moenks, S. Stanzel, A. Lukas, and A. Kopp-Schneider Transcriptomic hepatotoxicity signature of chlorpromazine after short- and long-term exposure in primary human sandwich cultures Drug Metab. Dispos. 41 2013 1835 1842
237. J. Surendradoss, T.K. Chang, and F.S. Abbott Evaluation of in situ generated valproyl 1-O-β-acyl glucuronide in valproic acid toxicity in sandwich-cultured rat hepatocytes Drug Metab. Dispos. 2014
238. A.V. Janorkar, L.M. Harris, B.S. Murphey, and B.L. Sowell Use of three-dimensional spheroids of hepatocyte-derived reporter cells to study the effects of intracellular fat accumulation and subsequent cytokine exposure Biotechnol. Bioeng. 108 2011 1171 1180
239. L.H. Damelin, S. Coward, M. Kirwan, P. Collins, C. Selden, and H.J. Hodgson Fat-loaded HepG2 spheroids exhibit enhanced protection from Pro-oxidant and cytokine induced damage J. Cell. Biochem. 101 2007 723 734
240. Y. Lu, G. Zhang, C. Shen, K. Uygun, M.L. Yarmush, and Q. Meng A novel 3D liver organoid system for elucidation of hepatic glucose metabolism Biotechnol. Bioeng. 109 2012 595 604
241. I.A. Graaf, G.M. Groothuis, and P. Olinga Precision-cut tissue slices as a tool to predict metabolism of novel drugs Expert Opin. Drug Metab. Toxicol. 3 2007 879 898
242. C.J. Green, C. Pramfalk, K.J. Morten, and L. Hodson From whole body to cellular models of hepatic triglyceride metabolism: man has got to know his limitations Am. J. Physiol. Endocrinol. Metab. 308 2015 E1 E20
243. E. Szalowska, B. van der Burg, H.Y. Man, P.J. Hendriksen, and A.A. Peijnenburg Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices PLoS One 9 2014 e86795
244. F. Nassir, O.L. Adewole, E.M. Brunt, and N.A. Abumrad CD36 deletion reduces VLDL secretion, modulates liver prostaglandins, and exacerbates hepatic steatosis in ob/ob mice J. Lipid Res. 54 2013 2988 2997
245. V. Tryndyak, O. Kovalchuk, and I.P. Pogribny Identification of differentially methylated sites within unmethylated DNA domains in normal and cancer cells Anal. Biochem. 356 2006 202 207
246. H.J. Jun, J. Kim, M.H. Hoang, and S.J. Lee Hepatic lipid accumulation alters global histone h3 lysine 9 and 4 trimethylation in the peroxisome proliferator-activated receptor alpha network PLoS One 7 2012 e44345
247. C.J. Pirola, T.F. Gianotti, A.L. Burgueño, M. Rey-Funes, C.F. Loidl, and P. Mallardi Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease Gut 62 2013 1356 1363
248. S. Sookoian, M.S. Rosselli, C. Gemma, A.L. Burgueño, T. Fernández Gianotti, and G.O. Castaño Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter Hepatology 52 2010 1992 2000
249. C. Esau, S. Davis, S.F. Murray, X.X. Yu, S.K. Pandey, and M. Pear MiR-122 regulation of lipid metabolism revealed by in vivo antisense targeting Cell Metab. 3 2006 87 98
250. C. Coulouarn, V.M. Factor, J.B. Andersen, M.E. Durkin, and S.S. Thorgeirsson Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties Oncogene 28 2009 3526 3536
251. C.L. Jopling, M. Yi, A.M. Lancaster, S.M. Lemon, and P. Sarnow Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA Science 309 2005 1577 1581
252. O. Cheung, P. Puri, C. Eicken, M.J. Contos, F. Mirshahi, and J.W. Maher Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression Hepatology 48 2008 1810 1820
253. C.J. Pirola, T. Fernández Gianotti, G.O. Castaño, P. Mallardi, J. San Martino, and M. Mora Gonzalez Lopez Ledesma Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis Gut 2014
254. H. Yamada, K. Suzuki, N. Ichino, Y. Ando, A. Sawada, and K. Osakabe Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver Clin. Chim. Acta 424 2013 99 103
255. S. Cermelli, A. Ruggieri, J.A. Marrero, G.N. Ioannou, and L. Beretta Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease PLoS One 6 2011 e23937
256. S.H. Hsu, B. Wang, J. Kota, J. Yu, S. Costinean, and H. Kutay Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver J. Clin. Invest. 122 2012 2871 2883
257. A.N. Mattis, G. Song, K. Hitchner, R.Y. Kim, A.Y. Lee, and A.D. Sharma A screen in mice uncovers repression of lipoprotein lipase by microRNA-29a as a mechanism for lipid distribution away from the liver Hepatology 2014
258. I.P. Pogribny, A. Starlard-Davenport, V.P. Tryndyak, T. Han, S.A. Ross, and I. Rusyn Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice Lab. Invest. 90 2010 1437 1446
259. A. Alisi, L. Da Sacco, G. Bruscalupi, F. Piemonte, N. Panera, and R. De Vito Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease Lab. Invest. 91 2011 283 293
260. S. Vella, D. Gnani, A. Crudele, S. Ceccarelli, C. De Stefanis, and S. Gaspari EZH2 down-regulation exacerbates lipid accumulation and inflammation in in vitro and in vivo NAFLD Int. J. Mol. Sci. 14 2013 24154 24168
261. J. Lee, and J.K. Kemper Controlling SIRT1 expression by microRNAs in health and metabolic disease Aging (Albany NY) 2 2010 527 534
262. M. Trajkovski, J. Hausser, J. Soutschek, B. Bhat, A. Akin, and M. Zavolan MicroRNAs 103 and 107 regulate insulin sensitivity Nature 474 2011 649 653
263. S.E. Choi, T. Fu, S. Seok, D.H. Kim, E. Yu, and K.W. Lee Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT Aging Cell 12 2013 1062 1072
264. S. Romeo, J. Kozlitina, C. Xing, A. Pertsemlidis, D. Cox, and L.A. Pennacchio Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease Nat. Genet. 40 2008 1461 1465
265. Y. Rotman, C. Koh, J.M. Zmuda, D.E. Kleiner, and T.J. Liang CRN N. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease Hepatology 52 2010 894 903
266. Y.L. Liu, G.L. Patman, J.B. Leathart, A.C. Piguet, A.D. Burt, and J.F. Dufour Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma J. Hepatol. 61 2014 75 81
267. Y.L. Liu, H.L. Reeves, A.D. Burt, D. Tiniakos, S. McPherson, and J.B. Leathart TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease Nat. Commun. 5 2014 4309
268. S. Kiziltas, P. Ata, Y. Colak, B. Mesçi, E. Senates, and F. Enc TLR4 gene polymorphism in patients with nonalcoholic fatty liver disease in comparison to healthy controls Metab. Syndr. Relat. Disord. 12 2014 165 170
269. G. Musso, S. Bo, M. Cassader, F. De Michieli, and R. Gambino Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism Am. J. Clin. Nutr. 98 2013 895 906
270. S.M. Zain, Z. Mohamed, and R. Mohamed A common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: A meta-analysis J. Gastroenterol. Hepatol. 30 2015 21 27
271. W. Zheng, L. Wang, X. Su, and X.F. Hu MTP-493G>T polymorphism and susceptibility to nonalcoholic fatty liver disease: a meta-analysis DNA Cell Biol. 33 2014 361 369
272. S. Petta, L. Miele, E. Bugianesi, C. Cammà, C. Rosso, and S. Boccia Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease PLoS One 9 2014 e87523
273. M.R. Li, S.H. Zhang, K. Chao, X.H. Liao, J.Y. Yao, and M.H. Chen Apolipoprotein C3 (-455T>C) polymorphism confers susceptibility to nonalcoholic fatty liver disease in the Southern Han Chinese population World J. Gastroenterol. 20 2014 14010 14017
274. S.L. Wood, J.A. Westbrook, and J.E. Brown Omic-profiling in breast cancer metastasis to bone: implications for mechanisms, biomarkers and treatment Cancer Treat. Rev. 40 2014 139 152
275. N. Guillén, M.A. Navarro, C. Arnal, E. Noone, J.M. Arbonés-Mainar, and S. Acín Microarray analysis of hepatic gene expression identifies new genes involved in steatotic liver Physiol. Genomics 37 2009 187 198
276. E.E. Hennig, M. Mikula, K. Goryca, A. Paziewska, J. Ledwon, and M. Nesteruk Extracellular matrix and cytochrome P450 gene expression can distinguish steatohepatitis from steatosis in mice J. Cell. Mol. Med. 18 2014 1762 1772
277. E. Xu, M.P. Forest, M. Schwab, R.K. Avramoglu, E. St-Amand, and A.Z. Caron Hepatocyte-specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: potential role of PPARγ Hepatology 59 2014 1803 1815
278. F. Chiappini, A. Barrier, R. Saffroy, M.C. Domart, N. Dagues, and D. Azoulay Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray Lab. Invest. 86 2006 154 165
279. J. Starmann, M. Fälth, W. Spindelböck, K.L. Lanz, C. Lackner, and K. Zatloukal Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis PLoS One 7 2012 e46584
280. L. Luo, L.Y. Dong, Q.G. Yan, S.J. Cao, X.T. Wen, and Y. Huang Research progress in applying proteomics technology to explore early diagnosis biomarkers of breast cancer, lung cancer and ovarian cancer Asian Pac. J. Cancer Prev. 15 2014 8529 8538
281. L. Zhang, G. Perdomo, D.H. Kim, S. Qu, S. Ringquist, and M. Trucco Proteomic analysis of fructose-induced fatty liver in hamsters Metabolism 57 2008 1115 1124
282. J.E. Park, H.T. Kim, S. Lee, Y.S. Lee, U.K. Choi, and J.H. Kang Differential expression of intermediate filaments in the process of developing hepatic steatosis Proteomics 11 2011 2777 2789
283. X. Hui, W. Zhu, Y. Wang, K.S. Lam, J. Zhang, and D. Wu Major urinary protein-1 increases energy expenditure and improves glucose intolerance through enhancing mitochondrial function in skeletal muscle of diabetic mice J. Biol. Chem. 284 2009 14050 14057
284. M. Suski, R. Olszanecki, J. Madej, J. Totoń-Zurańska, A. Niepsuj, and J. Jawień Proteomic analysis of changes in protein expression in liver mitochondria in apoE knockout mice J. Proteomics 74 2011 887 893
285. A. Thomas, A.P. Stevens, M.S. Klein, C. Hellerbrand, K. Dettmer, and W. Gronwald Early changes in the liver-soluble proteome from mice fed a nonalcoholic steatohepatitis inducing diet Proteomics 12 2012 1437 1451
286. G.H. Kim, E.C. Park, S.H. Yun, Y. Hong, D.G. Lee, and E.Y. Shin Proteomic and bioinformatic analysis of membrane proteome in type 2 diabetic mouse liver Proteomics 13 2013 1164 1179
287. I. Bondia-Pons, N. Boqué, L. Paternain, E. Santamaría, J. Fernández, and J. Campión Liver proteome changes induced by a short-term high-fat sucrose diet in wistar rats J. Nutrigenet. Nutrigenomics 4 2011 344 353
288. M. Charlton, K. Viker, A. Krishnan, S. Sanderson, B. Veldt, and A.J. Kaalsbeek Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease Hepatology 49 2009 1375 1384
289. W. Su, Y. Wang, X. Jia, W. Wu, L. Li, and X. Tian Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease Proc. Natl. Acad. Sci. U. S. A. 111 2014 11437 11442
290. S. Patel, and S. Ahmed Emerging field of metabolomics: big promise for cancer biomarker identification and drug discovery J. Pharm. Biomed. Anal. 107C 2014 63 74
291. H.J. Atherton, M.K. Gulston, N.J. Bailey, K.K. Cheng, W. Zhang, and K. Clarke Metabolomics of the interaction between PPAR-alpha and age in the PPAR-alpha-null mouse Mol. Syst. Biol. 5 2009 259
292. M. Vinaixa, M.A. Rodríguez, A. Rull, R. Beltrán, C. Bladé, and J. Brezmes Metabolomic assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease J. Proteome Res. 9 2010 2527 2538
293. L. Zhang, Y. Ye, Y. An, Y. Tian, Y. Wang, and H. Tang Systems responses of rats to aflatoxin B1 exposure revealed with metabonomic changes in multiple biological matrices J. Proteome Res. 10 2011 614 623
294. I. Rubio-Aliaga, B. Roos, M. Sailer, G.A. McLoughlin, M.V. Boekschoten, and M. van Erk Alterations in hepatic one-carbon metabolism and related pathways following a high-fat dietary intervention Physiol. Genomics 43 2011 408 416
295. Y. Macotela, B. Emanuelli, A.M. Bång, D.O. Espinoza, J. Boucher, and K. Beebe Dietary leucine - an environmental modifier of insulin resistance acting on multiple levels of metabolism PLoS One 6 2011 e21187
296. A. García-Heredia, E. Kensicki, R.P. Mohney, A. Rull, I. Triguero, and J. Marsillach Paraoxonase-1 deficiency is associated with severe liver steatosis in mice fed a high-fat high-cholesterol diet: a metabolomic approach J. Proteome Res. 12 2013 1946 1955
297. N. Tanaka, T. Matsubara, K.W. Krausz, A.D. Patterson, and F.J. Gonzalez Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis Hepatology 56 2012 118 129
298. N. Tanaka, S. Takahashi, Z.Z. Fang, T. Matsubara, K.W. Krausz, and A. Qu Role of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet Biochim. Biophys. Acta 1841 2014 1596 1607
299. M. Yamazaki, M. Miyake, H. Sato, N. Masutomi, N. Tsutsui, and K.P. Adam Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats Toxicol. Appl. Pharmacol. 268 2013 79 89
300. H. Li, L. Wang, X. Yan, Q. Liu, C. Yu, and H. Wei A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease J. Proteome Res. 10 2011 2797 2806
301. S.C. Kalhan, L. Guo, J. Edmison, S. Dasarathy, A.J. McCullough, and R.W. Hanson Plasma metabolomic profile in nonalcoholic fatty liver disease Metabolism 60 2011 404 413
302. A.D. Lake, P. Novak, P. Shipkova, N. Aranibar, D. Robertson, and M.D. Reily Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease Toxicol. Appl. Pharmacol. 268 2013 132 140
303. J.C. García-Cañaveras, M.T. Donato, J.V. Castell, and A. Lahoz A comprehensive untargeted metabonomic analysis of human steatotic liver tissue by RP and HILIC chromatography coupled to mass spectrometry reveals important metabolic alterations J. Proteome Res. 10 2011 4825 4834
304. V. Patel, and A.J. Sanyal Drug-induced steatohepatitis Clin. Liver Dis. 17 2013 533-46, vii
305. R. Mayeux Biomarkers: potential uses and limitations NeuroRx 1 2004 182 188
306. R. Buettner, J. Schölmerich, and L.C. Bollheimer High-fat diets: modeling the metabolic disorders of human obesity in rodents Obesity (Silver Spring) 15 2007 798 808
307. R.M. Rodrigues, J. De Kock, S. Branson, M. Vinken, K. Meganathan, and U. Chaudhari Human skin-derived stem cells as a novel cell source for in vitro hepatotoxicity screening of pharmaceuticals Stem Cells Dev. 23 2014 44 55
308. M. Itoh, T. Suganami, N. Nakagawa, M. Tanaka, Y. Yamamoto, and Y. Kamei Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis Am. J. Pathol. 179 2011 2454 2463
309. J.K. Reddy Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis Am. J. Physiol. Gastrointest. Liver Physiol. 281 2001 G1333 G1339
310. K. Nomoto, K. Tsuneyama, H.O. Abdel Aziz, H. Takahashi, Y. Murai, and Z.G. Cui Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice J. Pathol. 210 2006 469 477
311. J.A. Ibdah, H. Paul, Y. Zhao, S. Binford, K. Salleng, and M. Cline Lack of mitochondrial trifunctional protein in mice causes neonatal hypoglycemia and sudden death J. Clin. Invest. 107 2001 1403 1409
312. J.A. Ibdah, P. Perlegas, Y. Zhao, J. Angdisen, H. Borgerink, and M.K. Shadoan Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance Gastroenterology 128 2005 1381 1390
313. C.Y. Fan, J. Pan, R. Chu, D. Lee, K.D. Kluckman, and N. Usuda Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene J. Biol. Chem. 271 1996 24698 24710
314. Y. Horie, A. Suzuki, E. Kataoka, T. Sasaki, K. Hamada, and J. Sasaki Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas J. Clin. Invest. 113 2004 1774 1783
315. M.L. Martínez-Chantar, F.J. Corrales, L.A. Martínez-Cruz, E.R. García-Trevijano, Z.Z. Huang, and L. Chen Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A FASEB J. 16 2002 1292 1294
316. Y. Liu, M.D. Michael, S. Kash, W.R. Bensch, B.P. Monia, and S.F. Murray Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes Endocrinology 148 2007 683 692
317. T. Yamauchi, Y. Nio, T. Maki, M. Kobayashi, T. Takazawa, and M. Iwabu Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions Nat. Med. 13 2007 332 339
318. V.B. Matthews, T.L. Allen, S. Risis, M.H. Chan, D.C. Henstridge, and N. Watson Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance Diabetologia 53 2010 2431 2441
319. B. Kong, J.P. Luyendyk, O. Tawfik, and G.L. Guo Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet J. Pharmacol. Exp. Ther. 328 2009 116 122
320. R. Goel, B. Boylan, L. Gruman, P.J. Newman, P.E. North, and D.K. Newman The proinflammatory phenotype of PECAM-1-deficient mice results in atherogenic diet-induced steatohepatitis Am. J. Physiol. Gastrointest. Liver Physiol. 293 2007 G1205 G1214
321. K. Robert, J. Nehmé, E. Bourdon, G. Pivert, B. Friguet, and C. Delcayre Cystathionine beta synthase deficiency promotes oxidative stress, fibrosis, and steatosis in mice liver Gastroenterology 128 2005 1405 1415
322. M. Gary-Bobo, G. Elachouri, J.F. Gallas, P. Janiak, P. Marini, and C. Ravinet-Trillou Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats Hepatology 46 2007 122 129
323. S.M. Watkins, P.R. Reifsnyder, H.J. Pan, J.B. German, and E.H. Leiter Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone J. Lipid Res. 43 2002 1809 1817
324. V. van Ginneken, E. Verhey, R. Poelmann, R. Ramakers, K.W. van Dijk, and L. Ham Metabolomics (liver and blood profiling) in a mouse model in response to fasting: a study of hepatic steatosis Biochim. Biophys. Acta 1771 2007 1263 1270